A multimodal AI model identified a subset of men with very high-risk localized prostate cancer who derived substantial ...
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...
Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...
Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Please provide your email address to receive an email when new articles are posted on . MyProstateScore 2.0 showed high sensitivity for detecting aggressive prostate cancer without the need for a ...
Researchers have found a simple at home urine test for prostate cancer screening is highly accurate. Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine ...
WBRE Wilkes-Barre on MSN
Mark Hiller’s personal battle with prostate cancer
(WBRE/WYOU) — Prostate cancer is the second leading cancer in men. Earlier this year, I got the disturbing diagnosis that I ...
SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results